Wan Cheng Chow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6017003/publications.pdf

Version: 2024-02-01

933447 794594 21 434 10 citations h-index papers

19 g-index 22 22 22 855 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy. Gastroenterology, 2019, 156, 1862-1876.e9.	1.3	92
2	Reduction of HBV replication prolongs the early immunological response to IFNÎ \pm therapy. Journal of Hepatology, 2014, 60, 54-61.	3.7	75
3	Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut, 2022, 71, 854-863.	12.1	57
4	Perceptions of non-alcoholic fatty liver disease – an Asian community-based study. Gastroenterology Report, 2016, 4, 131-135.	1.3	38
5	Unhealthy lifestyle habits and physical inactivity among Asian patients with nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 2719-2731.	3.9	32
6	Immunosuppressive Drugâ€Resistant Armored Tâ€Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients. Hepatology, 2021, 74, 200-213.	7.3	29
7	Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure. Gastroenterology Report, 2015, 3, 122-127.	1.3	26
8	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 320-325.	2.8	23
9	Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up. Microbiology Insights, 2020, 13, 117863612091887.	2.0	13
10	Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Medical Journal, 2019, 60, 34-39.	0.6	12
11	Clinical profile of nonâ€alcoholic fatty liver disease in nonobese patients. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 257-261.	2.8	7
12	Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore. Singapore Medical Journal, 2019, 60, 532-537.	0.6	7
13	Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourableIL28Bpolymorphism. Gastroenterology Report, 2016, 5, gow033.	1.3	5
14	Hepatitis C virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in atâ€risk populations and immunocompromised hosts. Journal of Medical Virology, 2021, 93, 3738-3743.	5.0	3
15	Prescription patterns of outpatients and the potential of multiplexed pharmacogenomic testing. British Journal of Clinical Pharmacology, 2021, 87, 886-894.	2.4	3
16	Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy, 2021, 41, 332-341.	2.6	3
17	Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease. Digestive Diseases and Sciences, 2021, 66, 1343-1348.	2.3	3
18	Risk of Hepatitis B Virus (HBV) Reactivation and Role of Anti-Viral Prophylaxis in Lymphoma Patients with Past HBV Infection (HBV Antigen negative but anti-Hepatitis B core antibody positive) Receiving Chemo-Immunotherapy. Blood, 2008, 112, 3768-3768.	1.4	3

#	Article	IF	CITATIONS
19	A randomised clinical trial of the safety, cost effectiveness and patient experience of nurseâ€led telemonitoring of chronic hepatitis B patients. GastroHep, 2019, 1, 249-255.	0.6	2
20	Fructose intake in patients with non-alcoholic fatty liver disease. Proceedings of Singapore Healthcare, 2019, 28, 218-223.	0.6	1
21	Authors' reply: Comment on: Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Medical Journal, 2019, 60, 323-323.	0.6	O